Key highlights
02 March 2023 – 1 mins read
LinkedIn
Twitter
Facebook
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
PARIS, FRANCE, 3 March 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions. The acquisition enriches Ipsen’s Rare Disease portfolio, with…
Filter
Period
Filter by
recent search
Showing: 1 – 05 of 15 Corporate News
–
03 December 2024
03 December 2024
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
PARIS, FRANCE; 03 December 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Biomunex Pharmaceuticals today announced an exclusive global licensing agreement for BMX-502. BMX-502 is a bispecific antibody that engages and activates a subset of cytotoxic T cells called Mucosal-Associated…
–
30 August 2024
30 August 2024
Testing video 3
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type…
–
30 August 2024
30 August 2024
Testing video 2
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type…
–
11 July 2024
11 July 2024
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
PARIS, FRANCE, 11 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Foreseen Biotechnology (Foreseen) today announced an exclusive global licensing agreement for FS001, an antibody-drug conjugate (ADC) with first-in-class potential. FS001 targets a novel tumor-associated antigen that is overexpressed…
Your dedicated contacts
-
Craig Marks
Vice President, Investor Relations
-
-
Nicolas Bogler
Senior Manager, Investor Relations
-